## **CLAIMS**:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## 1. to 4. (Canceled).

- 5. (Currently Amended) A method for evaluating a change in HIV drug susceptibility of HIV, comprising:
  - (i) collecting a sample from an HIV-infected patient;
  - (ii) determining whether the sample comprises a an HIV having a reverse transcriptase having containing a mutation 386AT386A;
  - (iii) determining the viral drug susceptibility of HIV to an HIV reverse transcriptase inhibitor in said sample;
  - (iv) comparing the drug susceptibility in said sample containing said mutation 386AT386A with drug susceptibility in a sample containing a wild type HIV reverse transcriptase; and
  - (v) correlating the presence of said mutation of step (ii) to a change in viral drug susceptibility of HIV to said inhibitor.
- 6. (Currently Amended) A method of evaluating a change in HIV drug susceptibility of HIV, comprising:
  - (i) providing an HIV comprising a reverse transcriptase containing a mutation 386AT386A;
  - (ii) determining a phenotypic response of said virus <u>HIV</u> to said drug an <u>HIV</u> reverse transcriptase inhibitor;
  - (iii) determining the viral-drug susceptibility of said HIV to said inhibitor in said sample;
  - (iv) comparing the drug susceptibility in said sample containing said mutation 386A-T386A with drug susceptibility in a sample containing a wild type HIV reverse transcriptase; and
  - (v) correlating the phenotypic response of step (ii) to a change in viral-drug susceptibility of said HIV to said inhibitor.

7. to 10. (Canceled)